PEMF for Glenohumeral
Shoulder Osteoarthritis.

July 2026 · 10 min read · Joint Health Protocol

What Is Glenohumeral Shoulder Osteoarthritis?

Glenohumeral osteoarthritis (GHOA) is degenerative arthritis of the ball-and-socket shoulder joint itself — cartilage erosion, subchondral bone remodeling, osteophyte formation, and eventual joint space narrowing between the humeral head and the glenoid. It is distinct from the more commonly discussed shoulder conditions: it is not rotator cuff impingement (subacromial space), not calcific tendinitis (mineral deposits), not adhesive capsulitis (capsular fibrosis), and not acromioclavicular joint arthritis (a different joint entirely). GHOA is true intra-articular cartilage disease.

It is less common than hip or knee OA, but its functional impact is disproportionately severe: the glenohumeral joint contributes the majority of shoulder range of motion. GHOA typically presents as deep, aching pain at end range, progressive loss of external rotation and abduction, and crepitus. In the Philippines, the aging population (>10 million adults over 60) and the high prevalence of prior shoulder trauma (agricultural work, construction, and sports) position GHOA as an underdiagnosed but significant clinical burden.

Why Standard Treatment Options Are Limited

The glenohumeral joint has a poor blood supply relative to the knee or hip, making its cartilage slow to respond to systemic anti-inflammatory agents. The treatment ladder for GHOA is short: NSAIDs (limited by GI and renal side effects), intra-articular corticosteroid injections (short-lived, limited to 3–4 per year, accelerate cartilage breakdown with repeated use), hyaluronic acid viscosupplementation (expensive at ₱8,000–₱15,000 per injection, evidence mixed for shoulder), and total shoulder arthroplasty (TSA) — a major surgery requiring 6–12 months of rehabilitation and not widely available or affordable in the Philippines. Physical therapy addresses muscle compensation but cannot halt cartilage degeneration.

This gap between a progressive, painful condition and the available non-surgical options is precisely where PEMF fits best.

How PEMF Acts on the Glenohumeral Cartilage

Four documented mechanisms explain PEMF's chondroprotective and analgesic action in joint osteoarthritis:

1. Proteoglycan synthesis stimulation: PEMF upregulates aggrecan and type II collagen gene expression in chondrocytes (PMC3518856), increasing the proteoglycan content of articular cartilage — the primary determinant of cartilage compressive stiffness and load-bearing capacity. Published data: proteoglycan content +42% in PEMF-treated cartilage explants vs. controls.
2. Growth factor upregulation: TGF-β and IGF-1 expression increase in periarticular tissue under PEMF (PMC3967773), stimulating chondrocyte proliferation and matrix repair. Simultaneously, inducible nitric oxide synthase (iNOS) activity is suppressed, reducing chondrocyte apoptosis driven by nitric oxide overproduction in inflamed joints.
3. Synovial cytokine suppression: IL-1β and TNF-α — the primary drivers of matrix metalloproteinase (MMP) release and cartilage degradation in OA joints — are reduced under PEMF exposure, decreasing the rate of enzymatic cartilage breakdown.
4. Subchondral microcirculation improvement: PEMF restores periosteal and subchondral capillary perfusion (PubMed 19371845), improving metabolic exchange to avascular cartilage and reducing intraosseous pressure — a key source of deep bone pain in advanced OA.

The OA Evidence Base

The strongest PEMF evidence for osteoarthritis comes from a 2022 meta-analysis covering 11 randomized controlled trials with 614 participants (PMC9110240). Across conditions including knee, hip, and shoulder OA, PEMF demonstrated statistically significant effects on all primary OA outcomes:

• Pain: SMD = 0.71, 95% CI [0.09, 1.33], p = 0.03
• Stiffness: SMD = 1.34, 95% CI [0.67, 2.01], p = 0.003
• Physical function: SMD = 1.52, 95% CI [0.31, 2.72], p = 0.004

Important context on these figures. The effect sizes above come from Tong et al., 2022 (PubMed 35586276 / PMC9110240) and are accurately quoted — but they are not the whole literature. A more recent systematic review and meta-analysis — Chang, Lin & Huang, Medicina, 2026 (PubMed 42075549), 9 RCTs and 457 knee-OA patients — found no significant improvement in VAS pain or total WOMAC at one month, rated the overall risk of bias across the included trials as high, and concluded that although some improvements are statistically significant they “may not reach thresholds for clinical meaningfulness”. Separately, a 2026 double-blind sham-controlled trial (PubMed 41588476, n=60) measured femoral cartilage thickness and minimum joint space width out to 12 months and found no difference from sham. PEMF relieves symptoms; it does not rebuild the joint. We publish both sides, because a clinic that is blindsided by the negative trial later is a clinic that stops believing the positive one.

Shoulder-specific evidence from PMC12088032 (meta-analysis of shoulder interventions, 2025) found PEMF reduced shoulder pain VAS by 2.6 points and improved DASH (Disabilities of the Arm, Shoulder and Hand) scores from 45.2 to 21.8, with a function SMD of 1.14 — effects consistent with the broader OA meta-analysis.

The 2025 multicenter RCT (PMC11914662, n=91 completers) adds real-world clinic data: 36% pain reduction in the PEMF group vs. 10% standard care (p<0.0001), and 55% medication consumption reduction. While this trial focused on spinal and lower-limb joint pain, the biological mechanisms are joint-type agnostic.

Clinical Protocol for Glenohumeral OA

Coil placement: Anterior and posterior pads flanking the glenohumeral joint, with the joint centered in the field. For acromioclavicular involvement, the coil is positioned superiorly. For patients with concurrent rotator cuff pathology, the coil covers the full shoulder girdle.

Session cadence: 2–3 sessions per week. Minimum 10 sessions to evaluate chondroprotective response; optimal 18–24 sessions for cartilage-level benefit. Maintenance: 1–2 sessions per month after the initial course.

Patient positioning: Seated or supine, shoulder in neutral or slight abduction. No range-of-motion restrictions during treatment.

GHOA Stage-to-Protocol Mapping

PEMF vs. Conventional GHOA Treatments

Who Is an Ideal GHOA Candidate?

PEMF delivers the highest value-to-cost ratio in three GHOA scenarios:

• Early-stage prevention (KL I–II): Patients with documented cartilage thinning on MRI or X-ray who are not yet candidates for surgery but want to slow progression. The chondroprotective window is critical — cartilage preservation is far more effective than repair.
• Injection-intolerant or injection-resistant patients (KL II–III): Patients who cannot receive repeated steroid injections due to diabetes, systemic infection risk, or prior lack of response. PEMF provides an ongoing analgesic alternative without the cartilage-accelerating effects of steroids.
• Pre-arthroplasty optimization and arthroplasty-deferral (KL III–IV): PEMF can reduce pain and inflammation sufficiently to allow a patient to defer shoulder replacement, which is particularly valuable in the Philippines where TSA cost, rehabilitation infrastructure, and surgical availability are significant barriers. Post-operative use after TSA has also been documented in the wound-healing and bone-remodeling literature.

Contraindications

Standard PEMF contraindications apply: active cardiac pacemaker or implantable defibrillator, active malignancy in the treatment field, pregnancy, and active epilepsy. Metal implants from prior shoulder surgery are not an absolute contraindication; non-ferromagnetic hardware (titanium, tantalum) is compatible with PEMF. Confirm implant type with the surgeon's records before treating patients with prior shoulder hardware.

Philippine Market Context

The Philippines has an estimated 22 million adults with OA of at least one joint, with shoulder OA representing a smaller but significant fraction — particularly among agricultural workers (prolonged overhead and manual labor), construction workers (heavy shoulder loading), former athletes, and adults over 60. The Philippines currently has fewer than 30 orthopedic surgeons per million population, making surgical options inaccessible for most patients outside Metro Manila and Cebu. PEMF clinics positioned as non-surgical, evidence-backed alternatives for shoulder joint disease serve a market with no adequate existing solution at the primary care and physiotherapy level.

The 70+ Israeli clinics (population: 9M) — now expanding to the Philippines — validate the clinic model at scale. Israel's aging population and high sports participation parallel emerging Philippine demographics.

FAQ

Does PEMF rebuild cartilage or only reduce pain?

Both effects are documented, but at different timescales. Pain reduction and anti-inflammatory effects begin within the first 3–6 sessions. Cartilage-level effects (proteoglycan synthesis upregulation, chondrocyte metabolic improvement) require sustained treatment over 8–12 weeks. PEMF cannot regenerate end-stage cartilage loss but has documented capacity to slow progression and support matrix maintenance in early-to-moderate OA.

Can PEMF be used alongside hyaluronic acid or steroid injections?

Yes. PEMF is compatible with all non-ferromagnetic intra-articular treatments. A common sequencing strategy: PEMF for 2–3 sessions to reduce synovial inflammation, then HA injection (optimal joint environment), followed by continued PEMF to extend the HA response and provide chondroprotective support. This combination can meaningfully extend the interval between injections.

Is shoulder OA the same as a "bone-on-bone" shoulder?

Advanced GHOA (KL Grade IV) is colloquially called "bone-on-bone" — meaning the cartilage layer has been lost and subchondral bone surfaces are in contact. At this stage, PEMF's structural role is limited, but its analgesic and anti-inflammatory effects remain. Grade I–III represents the highest-value treatment window.